ARTICLE SUMMARY:
In January, iRhythm Technologies gained solid clinical validation in the form of a category I CPT code for its extended Holter monitoring platform, but the good news was quickly overshadowed by a much lower than expected reimbursement rate published by a key Medicare contractor.
To what degree does or should reimbursement reflect the clinical value of a new medical product, rather than the cost of delivering that medical innovation? That question is top of mind as investors in the ambulatory cardiac monitoring market watch the reimbursement saga of iRhythm Technologies Inc. and other companies affected by a recent reimbursement cut in the fastest-growing segment of ambulatory ECG monitoring.
